Lakewood-Amedex Biotherapeutics Inc. (LABT) Operating cash flow 2024–2025
Lakewood-Amedex Biotherapeutics Inc. (LABT) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$1.9MFY2025 · since FY2024: -$5.7M → -$1.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$1.9M | +66.0% |
| FY2024 | -$5.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More LABT financial trends
LABT RevenueLABT Net incomeLABT Net marginLABT Gross profitLABT Gross marginLABT Operating incomeLABT Operating marginLABT Free cash flowLABT Capital expendituresLABT Return on equityLABT Stock buybacksLABT Dividends paidLABT Total assetsLABT Total liabilitiesLABT Shareholders’ equityLABT overview →